Surgery – Miscellaneous – Methods
Patent
1997-10-03
1999-08-31
Yu, Mickey
Surgery
Miscellaneous
Methods
514 23, A61B 1900
Patent
active
059440201
ABSTRACT:
When fructose-1,6-diphosphate (FDP) is used as an inotropic drug in patients who have undergone surgery involving cardiopulmonary bypass, it can increase the pumping strength of a struggling heart, without increasing the heartbeat rate. As such, FDP can reduce the dosages of (and in some some cases eliminate the need for) other inotropic drugs such as dobutamine, epinephrin, or amrinone lactate, which have undesired and potentially dangerous side effects, mainly involving increasing the heartbeat rate, which imposes substantial additional stresses on hearts that are struggling to regain strength after cardiopulmonary bypass surgery.
REFERENCES:
patent: 4530902 (1985-07-01), Perri et al.
patent: 4546095 (1985-10-01), Markov
patent: 4575549 (1986-03-01), Diana et al.
patent: 4703040 (1987-10-01), Markov
patent: 4870057 (1989-09-01), Chiapparelli et al.
patent: 5039665 (1991-08-01), Markov
patent: 5094947 (1992-03-01), Nakajima et al.
patent: 5434255 (1995-07-01), Katayama et al.
patent: 5506210 (1996-04-01), Parish et al.
patent: 5516526 (1996-05-01), da la Torre
patent: 5571906 (1996-11-01), Ceccarelli et al.
patent: 5731291 (1998-03-01), Sullivan et al.
Angelos, M.G., et al, "Fructose-1,6-diphosphate fails to limit early myocardial infarction size in a canine model," Ann. Emerg. Med. 22: 171-177 (1993).
Brunswick, R., et al, "Preservation of myocardium by infusion of fructose diphosphate following coronary occlusion," abstract, Am J Cardiol 49: 1008 (1982).
Cargnoni, A., et al, "Role of timing of administration in the cardioprotective effect of fructose-1,6-bisphosphate," Cardiovasc Drugs Ther 6: 209-17 (1992).
Conti, V.R., et al, "Metabolic and functional effects of carbohydrate substrate with single-dose and multiple-dose potassium cardioplegia," Ann. Thoracic Surg. 36: 320-327 (1983).
Eddy, L.J., et al, "Lack of a direct metabolic effect of fructose, 1,6-diphosphate in ischemic myocardium," Am J Physiol 241: H576-83 (1995).
"Esafosfina" sales brochure (Biomedica Foscama; Ferentino, Italy).
Farias, L.A., et al, "Effects of fructose-1,6-diphosphate, glucose and saline on cardiac resuscitation," Anesthesiology 65: 595-601 (1986).
Granot, H., et al, "Successful treatment of irreversible hemorrhagic shock in dogs with fructose-1,6 diphosphate and dichloroacetate," Circ Shock 163-73 (1985).
Haasinen, I.E., et al, "Mechanism of the effect of exogenous FDP on myocardial energy metabolism," Circulation 83: 584-593 (1991).
Lazzarino G., et al, "Protective effects of exogenously administered fructose-1,6-diphosphate from ischemia reperfusion damage induced on isolated rat heart," Ital J Biochem 38: 251A-253A (1989).
Lazzarino, G., et al, "Ischemia and reperfusion: effect of fructose-1,6-bisphosphate," Free Radic Res Commun 16: 325-39 (1992).
Marchionni, N., et al, "Hemodynamic and electrocardio-graphic effects of fructose-1,6-diphosphate in acute myocardial infarction," Am J Cardiol 56: 266-269 (1985).
Markov, A.K., et al, "Prevention of arrhythmias with fructose diphosphate in acute myocardial ischemia," abstract, Circulation 62: III-143 (1980).
Markov, A.K., et al, "Hemodynamic, electrocardiographic, and metabolic effects of fructose diphosphate on acute myocardial ischemia," Am Heart J 100: 639-46 (1980).
Markov, A.K., "Hemodynamics and metabolic effects of fructose 1-6 diphosphate in ischemia and shock--experimental and clinical observations," Ann Emerg Med 15: 1470-7 (1986).
Markov, A.K., et al, "Increasing survival of dogs subjected to hemorrhagic shock by administration of fructose 1-6 diphosphate," Surgery 102: 515-27 (1987).
Markov, A.K., et al, "Improvement of hemodynamics and pulmonary function following fructose 1-6 diphosphate administration in ARDS patients," Microcirculation 1: 173-178 (1987).
Pasque, M.K., et a, "Metabolic intervention to affect myocardial recovery following ischemia," Annals of Surgery 200: 1-12 (1984).
Sernov, L.N., et al, "The characteristics of the cardioprotective action of fructose-1,6-diphosphate," Biull Eksp Biol Med 111:172-3 (1991) (abstract).
Sernov, L.N., et al, "The antiacidotic and cardio-protective effects of fructose-1,6-diphosphate and dehydroascorbic acid," Farmakol Toksikol 54:24-26 (1991) (abstract).
Sernov, L.N., et al, "A comparative evaluation of the cardioprotective and antianginal actions of energy-providing agents," Eksp Klin Farmakol 55:13-15 (1992) (abstract).
Stryer, L., Biochemistry, 2nd ed., pp. 266-267 (Freeman & Co., San Francisco, 1981).
Zhang, J.N., et al, "Protective effect of exogenous fructose-1,6-diphosphate in cardiogenic shock," Cardiovasc Res 22: 927-32 (1988).
Fox Anthony W.
Marangos Paul J.
Markov Angel K.
Cypros Pharmaceutical Corp.
Kelly Patrick D.
O'Hara Kelly
Yu Mickey
LandOfFree
Use of fructose-1 6-diphosphate as an inotrope drug after cardio does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of fructose-1 6-diphosphate as an inotrope drug after cardio, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of fructose-1 6-diphosphate as an inotrope drug after cardio will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2423416